Elosulfase alfa · VIMIZIM
Protein / enzyme therapeutic
Evidence outlook
Approved: Mucopolysaccharidosis Type IVA
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
track record: Partial signal
Also approved (3)
- MPS IVA (Morquio A syndrome)
- MPS IVA (Morquio A syndrome)
- Mucopolysaccharidosis type IVA (Morquio A syndrome)
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
| Trial | Phase | Endpoint | Key result | Signal | Source |
|---|---|---|---|---|---|
NCT01275066 NCT01275066 · Mucopolysaccharidosis Type IVA This randomized, quadruple-blind, placebo-controlled Phase 3 trial enrolled 177 patients with Morquio A syndrome and tested elosulfase alfa 2.0 mg/kg weekly or every other week against placebo for 24 weeks. On the primary endpoint, change in 6-minute walk distance, weekly dosing improved walk distance by 22.5 m more than placebo (p=0.0174, significant under the trial's multiplicity rule), while every-other-week dosing showed no difference (0.5 m, p=0.9542). The primary result was therefore met for one dosing regimen and missed for the other, and the record reported no power calculation or planned enrolment. Registry: NCT01275066 | 3 | Change From Baseline in Endurance as Measured by the 6-minute Walk Test (Baseline to Week 24) 2012-08 | Change From Baseline in Endurance as Measured by the 6-minute Walk Test (Baseline to Week 24): Placebo — Baseline: 211.9 meters (Standard Deviation 69.88); Week 24: 225.4 meters (Standard Deviation 83.22); Change from Baseline to Week 24: 13.5 meters (Standard Deviation 50.63) | BMN110 2.0 mg/kg/Qow — Baseline: 205.7 meters (Standard Deviation 81.19); Week 24: 219.9 meters (Standard Deviation 87.6); Change from Baseline to Week 24: 14.2 meters (Standard Deviation 40.82) | BMN110 2.0 mg/kg/Week — Baseline: 203.9 meters (Standard Deviation 76.32); Week 24: 240 meters (Standard Deviation 86.61); Change from Baseline to Week 24: 36 meters (Standard Deviation 58.11) | Partial signal | link ↗ |
View 1 more trial
NCT01415427 NCT01415427 · Mucopolysaccharidosis Type IVA This phase 3 study enrolled 173 patients with Morquio A syndrome who had completed the earlier randomized, placebo-controlled MOR-004 trial. Participants were first randomized, with masking, to weekly or every-other-week elosulfase alfa and then all received weekly dosing, so the study had no placebo comparison. The primary endpoint was change from baseline in 6-minute walk distance, reported descriptively without a statistical test; in the intention-to-treat population the mean change at week 168 was 8.9 metres. Registry: NCT01415427 | 3 | Change From Baseline in 6-minute Walk (6MW) Test - ITT (Baseline to week 168); Change From Baseline in 6-minute Walk (6MW) Test - MPP (Baseline to week 168) 2016-06-16 | Completed. Key figures are not recorded here; the rationale explains the result. | Partial signal | link ↗ |
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.
Phase 3 (3)
What this study did
What this study did
What this study did
Phase 2 (3)
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Competitive landscape
No competitors sharing a mechanism or indication in the current universe.
Upcoming events
No upcoming readouts on record for this asset.